Five Prime Therapeutics buy melinda
Startpreis
21.08.18
/
50%
12,08 €
Kursziel
20.09.18
13,98 €
Rendite (%)
6,80 %
Endpreis
20.09.18
12,90 €
Zusammenfassung
Diese Einschätzung wurde am 20.09.18 mit einem Endkurs von 12,90 € beendet. Die BUY Einschätzung von melinda zeigte mit einer Rendite von 6,80 % einen positiven Trend. melinda hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Five Prime Therapeutics | - | - | - | - |
| iShares Core DAX® | 0,00 % | -2,06 % | 13,11 % | 16,68 % |
| iShares Nasdaq 100 | 0,63 % | -2,88 % | 37,74 % | 43,44 % |
| iShares Nikkei 225® | 1,57 % | -5,89 % | 19,59 % | 4,62 % |
| iShares S&P 500 | 0,33 % | -2,28 % | 27,74 % | 41,05 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Five Prime Therapeutics diskutieren
SecteurRecherche biotechnologique et médicale Agenda 13/11 Publication de résultats
Discovers and develops protein therapeutics
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.
The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers.
The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer.
The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that are developing as a monotherapy in multiple cancers.
The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.
The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers.
The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer.
The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that are developing as a monotherapy in multiple cancers.
The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.
Nombre d'employés : 216 personnes.
(Vom Mitglied beendet)
Beendete Einschätzungen von melinda zu Five Prime Therapeutics
Five Prime Therapeutics
Startkurs
Kursziel
Rendite (%)
12,11 €
03.04.19
03.04.19
18,04 €
04.11.21
04.11.21
159,21 %
05.11.21
05.11.21
Five Prime Therapeutics
Startkurs
Kursziel
Rendite (%)
33,29 €
03.04.17
03.04.17
40,59 €
20.10.17
20.10.17
25,79 %
20.10.17
20.10.17